Year wrapped: Orthocell targets 2025 growth with FDA plans & product launches [Video]

Orthocell Ltd (ASX:OCC, OTC:ORHHF) chairman John Van Der Wielen talks with Proactive’s Tylah Tully about milestones achieved by the company this year and shared insights into its growth outlook for 2025.

Van Der Wielen highlighted Orthocell’s focus on execution, emphasising clinical and regulatory successes for key products Striate+™ and Remplir™.

The company secured approvals in Singapore and is preparing for a significant market entry into the United States, including an FDA application for Remplir™.

Van Der Wielen noted, “Our biggest achievement has been focusing on products that generate revenue while expanding into new markets globally.”

Orthocell also achieved its first sales in Singapore following product clearance in October, reflecting strong commercial momentum.

Further regulatory submissions for the SmartGraf tendon repair product are pending with the TGA, targeting the global tendon repair market.

Van Der Wielen also discussed Orthocell’s share price growth, attributing the performance to tangible clinical outcomes and expanding revenue streams.

“This is no longer speculative,” he stated. “Our products are changing lives and being used in human bodies worldwide.”

Looking ahead, Orthocell plans to launch Striate+™ into Austria and Switzerland and advance Remplir™ in the US, setting up significant revenue growth into 2025.

#ProactiveInvestors #Orthocell #ASX #OTC #US #MedicalDevices #FDAApproval #StriatePlus #Remplir #Orthobiologics #TendonRepair #HealthcareInnovation #BiotechInvesting #ClinicalSuccess #ASX #Growth2024#ProactiveInvestors#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews